S&P 500   3,337.59 (-1.06%)
DOW   28,914.06 (-1.05%)
QQQ   231.39 (-1.44%)
AAPL   316.84 (-1.08%)
FB   210.91 (-1.71%)
MSFT   180.39 (-2.19%)
GOOGL   1,502.44 (-0.96%)
AMZN   2,113.89 (-1.82%)
CGC   22.13 (-0.81%)
NVDA   297.45 (-3.64%)
MU   57.37 (-2.76%)
TSLA   888.68 (-1.19%)
AMD   55.21 (-3.60%)
T   38.51 (-0.26%)
ACB   1.66 (-1.19%)
F   7.93 (-1.25%)
NFLX   381.60 (-1.14%)
PRI   132.73 (-2.69%)
DIS   139.02 (-0.96%)
GILD   68.81 (+2.70%)
S&P 500   3,337.59 (-1.06%)
DOW   28,914.06 (-1.05%)
QQQ   231.39 (-1.44%)
AAPL   316.84 (-1.08%)
FB   210.91 (-1.71%)
MSFT   180.39 (-2.19%)
GOOGL   1,502.44 (-0.96%)
AMZN   2,113.89 (-1.82%)
CGC   22.13 (-0.81%)
NVDA   297.45 (-3.64%)
MU   57.37 (-2.76%)
TSLA   888.68 (-1.19%)
AMD   55.21 (-3.60%)
T   38.51 (-0.26%)
ACB   1.66 (-1.19%)
F   7.93 (-1.25%)
NFLX   381.60 (-1.14%)
PRI   132.73 (-2.69%)
DIS   139.02 (-0.96%)
GILD   68.81 (+2.70%)
S&P 500   3,337.59 (-1.06%)
DOW   28,914.06 (-1.05%)
QQQ   231.39 (-1.44%)
AAPL   316.84 (-1.08%)
FB   210.91 (-1.71%)
MSFT   180.39 (-2.19%)
GOOGL   1,502.44 (-0.96%)
AMZN   2,113.89 (-1.82%)
CGC   22.13 (-0.81%)
NVDA   297.45 (-3.64%)
MU   57.37 (-2.76%)
TSLA   888.68 (-1.19%)
AMD   55.21 (-3.60%)
T   38.51 (-0.26%)
ACB   1.66 (-1.19%)
F   7.93 (-1.25%)
NFLX   381.60 (-1.14%)
PRI   132.73 (-2.69%)
DIS   139.02 (-0.96%)
GILD   68.81 (+2.70%)
S&P 500   3,337.59 (-1.06%)
DOW   28,914.06 (-1.05%)
QQQ   231.39 (-1.44%)
AAPL   316.84 (-1.08%)
FB   210.91 (-1.71%)
MSFT   180.39 (-2.19%)
GOOGL   1,502.44 (-0.96%)
AMZN   2,113.89 (-1.82%)
CGC   22.13 (-0.81%)
NVDA   297.45 (-3.64%)
MU   57.37 (-2.76%)
TSLA   888.68 (-1.19%)
AMD   55.21 (-3.60%)
T   38.51 (-0.26%)
ACB   1.66 (-1.19%)
F   7.93 (-1.25%)
NFLX   381.60 (-1.14%)
PRI   132.73 (-2.69%)
DIS   139.02 (-0.96%)
GILD   68.81 (+2.70%)
Log in

NASDAQ:MLND - Millendo Therapeutics Stock Price, Forecast & News

$8.90
-0.22 (-2.41 %)
(As of 02/21/2020 10:43 AM ET)
Today's Range
$8.90
Now: $8.90
$9.20
50-Day Range
$6.68
MA: $7.83
$9.25
52-Week Range
$4.56
Now: $8.90
$17.34
Volume11,108 shs
Average Volume89,574 shs
Market Capitalization$119.88 million
P/E RatioN/A
Dividend YieldN/A
Beta2.78
Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome. The company is based in Ann Arbor, Michigan.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MLND
CUSIPN/A
CIKN/A
Phone734-845-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$290,000.00
Book Value$5.66 per share

Profitability

Net Income$-27,190,000.00

Miscellaneous

Employees32
Market Cap$119.88 million
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable

Receive MLND News and Ratings via Email

Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter.


Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions

What is Millendo Therapeutics' stock symbol?

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

How were Millendo Therapeutics' earnings last quarter?

Millendo Therapeutics Inc (NASDAQ:MLND) released its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.83) by $0.04. View Millendo Therapeutics' Earnings History.

When is Millendo Therapeutics' next earnings date?

Millendo Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Millendo Therapeutics.

What price target have analysts set for MLND?

7 Wall Street analysts have issued 1-year price targets for Millendo Therapeutics' stock. Their forecasts range from $22.00 to $35.00. On average, they expect Millendo Therapeutics' share price to reach $25.83 in the next year. This suggests a possible upside of 188.0% from the stock's current price. View Analyst Price Targets for Millendo Therapeutics.

What is the consensus analysts' recommendation for Millendo Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Millendo Therapeutics.

Has Millendo Therapeutics been receiving favorable news coverage?

News stories about MLND stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Millendo Therapeutics earned a news impact score of -2.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Millendo Therapeutics.

Are investors shorting Millendo Therapeutics?

Millendo Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 137,800 shares, an increase of 9.7% from the January 15th total of 125,600 shares. Based on an average daily trading volume, of 63,300 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.3% of the shares of the company are short sold. View Millendo Therapeutics' Current Options Chain.

Who are some of Millendo Therapeutics' key competitors?

What other stocks do shareholders of Millendo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include AbbVie (ABBV), Crispr Therapeutics (CRSP), OrganiGram (OGI), Sorrento Therapeutics (SRNE), Aurora Cannabis (ACB), International Paper (IP), Kadmon (KDMN), Adobe (ADBE), ADMA Biologics (ADMA) and Bellicum Pharmaceuticals (BLCM).

Who are Millendo Therapeutics' key executives?

Millendo Therapeutics' management team includes the folowing people:
  • Dr. Julia C. Owens Ph.D., CEO, Pres & Director (Age 45)
  • Dr. Gary Hammer M.D., Ph.D., Co-Founder and Chairman of Scientific Advisory Board
  • Mr. Louis J. Arcudi III, MBA, Chief Financial Officer (Age 58)
  • Mr. Jeffery M. Brinza J.D., Chief Admin. Officer, Gen. Counsel & Sec. (Age 57)
  • Dr. Pharis Mohideen, Chief Medical Officer (Age 54)

Who are Millendo Therapeutics' major shareholders?

Millendo Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Samsara BioCapital LLC (5.31%), Point72 Asset Management L.P. (4.34%), Renaissance Technologies LLC (1.54%), State Street Corp (1.24%), Monashee Investment Management LLC (1.04%) and Geode Capital Management LLC (0.75%).

Which institutional investors are buying Millendo Therapeutics stock?

MLND stock was bought by a variety of institutional investors in the last quarter, including Samsara BioCapital LLC, Point72 Asset Management L.P., Monashee Investment Management LLC, Geode Capital Management LLC, State Street Corp, Group One Trading L.P., Renaissance Technologies LLC and Tower Research Capital LLC TRC .

How do I buy shares of Millendo Therapeutics?

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Millendo Therapeutics' stock price today?

One share of MLND stock can currently be purchased for approximately $8.97.

How big of a company is Millendo Therapeutics?

Millendo Therapeutics has a market capitalization of $120.83 million and generates $290,000.00 in revenue each year. The company earns $-27,190,000.00 in net income (profit) each year or ($17.58) on an earnings per share basis. Millendo Therapeutics employs 32 workers across the globe.View Additional Information About Millendo Therapeutics.

What is Millendo Therapeutics' official website?

The official website for Millendo Therapeutics is http://www.millendo.com/.

How can I contact Millendo Therapeutics?

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MA, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]


MarketBeat Community Rating for Millendo Therapeutics (NASDAQ MLND)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  135
MarketBeat's community ratings are surveys of what our community members think about Millendo Therapeutics and other stocks. Vote "Outperform" if you believe MLND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: Price-Sales Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel